Takeaway

• Bezlotoxumab (BEZ) plus standard of care (SoC) appears to be more effective than SoC alone for preventing recurrent Clostridioides difficile ( C difficile ) infection (rCDI) and related mortality in a real-world hospital setting.
• The study was conducted by Italian researchers and appeared in the International Journal of Infectious ...